Emerging roles of the extracellular calcium-sensing receptor in nutrient sensing: control of taste modulation and intestinal hormone secretion

Sarah C. Brennan*, Thomas S. Davies, Martin Schepelmann and Daniela Riccardi*
Division of Pathophysiology and Repair, Cardiff School of Biosciences, Biomedical Sciences Building, Museum Avenue, Cardiff CF10 3AX, UK

(Submitted 10 September 2012 – Final revision received 9 January 2013 – Accepted 14 January 2013)

Abstract

The extracellular Ca-sensing receptor (CaSR) is a sensor for a number of key nutrients within the body, including Ca ions (\(\text{Ca}^{2+}\)) and \(\text{L}\)-amino acids. The CaSR is expressed in a number of specialised cells within the gastrointestinal (GI) tract, and much work has been done to examine CaSR’s role as a nutrient sensor in this system. This review article examines two emerging roles for the CaSR within the GI tract – as a mediator of kokumi taste modulation in taste cells and as a regulator of dietary hormone release in response to \(\text{L}\)-amino acids in the intestine.

Key words: Calcium-sensing receptor; Nutrient-sensing; Amino acids; Gastrointestinal tract; Taste modulation; Taste receptors

The Ca-sensing receptor (CaSR) is a class C G-protein-coupled receptor that was originally identified as the molecular ion sensor for free ionised extracellular Ca (\(\text{Ca}^{2+}\)) homeostasis(1). Although CaSR’s role in divalent cation metabolism has been well defined (reviewed by Brown & MacLeod(2) and Hofer & Brown(3)), the CaSR is expressed in a number of tissues and cell types not typically associated with \(\text{Ca}^{2+}\) homeostasis. Over the past few years, much work has been undertaken to elucidate the functional significance of CaSR expression in a wide number of other tissues including the brain and central nervous system(4), the vasculature(5) and the gastrointestinal (GI) tract.

Although the main physiological agonist of the CaSR is \(\text{Ca}^{2+}\), this receptor can be activated by a diverse array of other multivalent cations including alkaline metals (\(\text{Mg}^{2+}\) and \(\text{Sr}^{2+}\)), polycations (spermine and spermidine)(6), aminoglycoside antibiotics (neomycin and gentamicin)(7–9) and cationic polypeptides (poly-L-arginine)(10) (reviewed by Brown & MacLeod(2)). Changes in ionic strength (11) and pH (12) also affect CaSR’s activity, as low ionic strength and high pH enhance CaSR’s sensitivity to \(\text{Ca}^{2+}\).

Furthermore, as a class C G-protein-coupled receptor, the CaSR belongs to a family of extracellular amino acid sensors including the metabotropic glutamate receptors. The CaSR, along with the heterodimeric taste receptors (T1R1 and T1R3), and the goldfish 5.24 receptor and its mammalian orthologue GPRC6A form a distinct subgroup of broad-spectrum amino acid-sensing receptors, which have distinct yet overlapping sensitivities to different amino acids (Fig. 1).

The CaSR is allosterically activated by \(\text{L}\)-amino acids, being able to respond to aromatic, aliphatic and polar amino acids, but not to branched or positively charged amino acids(13). In contrast, taste receptors can be activated by aliphatic, polar, branched-chain and, to a lesser extent, charged amino acids, but not by aromatic amino acids. Lastly, the goldfish 5.24/GPRC6A receptors respond to basic, aliphatic and polar amino acids(14). The CaSR has also been shown to respond to small peptides, including glutathione and other \(\gamma\)-glutamyl peptides(15,16).

This variety in ligands enables the CaSR to act physiologically as a multi-modal sensor for several key nutrients throughout the body, including the GI tract. Within the GI tract, the CaSR is widely expressed in a number of specialised cells including the oesophagus, stomach, small intestine and colon(17–19) and has roles in gastrin secretion, colonic fluid transport and intestinal epithelial cell growth, all of which have been reviewed in depth previously (see Conigrave & Brown(19) and Hebert(20)) and are listed in Table 1. In this review article, we examine the emerging physiological functions of the CaSR in sensing dietary nutrients in two separate roles: (1) as a taste receptor for both protein and oral Ca\(^{2+}\) and (2) as an amino acid sensor for the release of dietary hormones within the intestine.

Abbreviations: \(\text{Ca}^{2+}\), intracellular \(\text{Ca}^{2+}\); \(\text{Ca}^{2+}\), ionised extracellular \(\text{Ca}^{2+}\); CaSR, Ca-sensing receptor; CCK, cholecystokinin; eGFP, enhanced green fluorescent protein; GI, gastrointestinal; PLC, phospholipase C.

*Corresponding authors: Dr S. C. Brennan, fax +44 29208 74116, email brennansc@cf.ac.uk; Professor D. Riccardi, fax +44 29208 74116, email riccardi@cf.ac.uk
Calcium-sensing receptor as a taste receptor

There is now emerging evidence suggesting that the CaSR may play a role in the regulation of appetite for nutrients by modulating taste perception. The first demonstration of the possible involvement of the CaSR in taste perception was given in bullfrogs, where a positive allosteric modulator of the CaSR, the ‘calcimimetic’ NPS R-467, stimulated taste cells with accompanying neuronal responses (21). Expression of the CaSR in rat and mouse taste cells, namely in the circumvallate, foliate and, to a lesser extent, the fungiform papillae, has recently been reported (22,23).

Taste buds are generally composed of approximately 50–100 elongated taste cells, which belong to three different classes: (i) Type I cells, which express the main taste receptor, (ii) Type II cells, which express a diverse array of taste receptors, and (iii) Type III cells, which express the CaSR.

Table 1. Known functions of the calcium-sensing receptor in the gastrointestinal tract

<table>
<thead>
<tr>
<th>Organ</th>
<th>Cell</th>
<th>Membrane localisation</th>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td>G cells</td>
<td>Basolateral and apical</td>
<td>Gastrin secretion</td>
<td>Buchan et al. (36)</td>
</tr>
<tr>
<td></td>
<td>Parietal cells</td>
<td>Basolateral</td>
<td>Cell growth</td>
<td>Feng et al. (56)</td>
</tr>
<tr>
<td>Intestine</td>
<td>Enteric nervous system cells</td>
<td>Basolateral and apical</td>
<td>Acid secretion (H⁺–K⁺ ATPase)</td>
<td>Cheng et al. (18)</td>
</tr>
<tr>
<td>Duodenum</td>
<td>I cells</td>
<td>Basolateral and apical</td>
<td>Gut motility and inhibition of fluid secretion</td>
<td>Dufner et al. (57)</td>
</tr>
<tr>
<td></td>
<td>K cells</td>
<td>Unknown</td>
<td>CCK secretion</td>
<td>Chattopadhyay et al. (17)</td>
</tr>
<tr>
<td></td>
<td>L cells</td>
<td>Basolateral and apical</td>
<td>GIP secretion</td>
<td>Liou et al. (48)</td>
</tr>
<tr>
<td></td>
<td>Colonocytes</td>
<td>Basolateral and apical</td>
<td>GLP-1 and PYY secretion</td>
<td>Mace et al. (52)</td>
</tr>
<tr>
<td></td>
<td>Colonocytes</td>
<td>Basolateral and apical</td>
<td>Inhibition of cell proliferation</td>
<td>Mace et al. (52)</td>
</tr>
<tr>
<td></td>
<td>Basolateral and apical</td>
<td>Stimulation of cell differentiation</td>
<td>Inhibition of ion/fluid secretion</td>
<td>Rey et al. (19a, 60)</td>
</tr>
<tr>
<td></td>
<td>Basolateral and apical</td>
<td>Basolateral and apical</td>
<td>Inhibition of fluid secretion</td>
<td>Geibel &amp; Hebert (36)</td>
</tr>
<tr>
<td></td>
<td>Basolateral and apical</td>
<td>Basolateral and apical</td>
<td>Stimulation of cell differentiation</td>
<td>Cheng (58)</td>
</tr>
</tbody>
</table>

CCK, cholecystokinin; GIP, gluco-inulotripic peptide; GLP-1, glucagon-like peptide 1; PYY, peptide tyrosine tyrosine.
classes\(^{(24,25)}\); type I (glial-like) cells, which seem to be involved in the clearance of neurotransmitters through absorption/degradation; type II (receptor) cells, which express G-protein-coupled receptors (including the taste receptors T1R and T2R), which bind to bitter, sweet and umami compounds, the downstream signalling components (e.g. phospholipase C\(\beta\)2 (PLC\(\beta\)2)) that transduce these taste qualities and the G-protein gustducin\(^{(26)}\); type III (presynaptic) cells, which form synaptic contacts with nerve terminals and are known to receive and integrate signals from type II cells.

Expression of the CaSR has been observed in type III taste cells at the mRNA and protein levels\(^{(22,23)}\), where the CaSR appears to be distributed throughout the plasma membrane; however, there have been conflicting reports on whether the CaSR is also expressed in type I and type II cells. Bystrova et al.\(^{(28)}\) showed CaSR mRNA expression at the single-cell level in a number of type I cells, but not in type II cells, using serial multistandard-assisted reverse transcriptase-polymerase chain reaction (SMART-PCR); however, they were unable to demonstrate functional coupling to the PLC-dependent \(\text{Ca}^{2+}\) signalling pathways in type I cells.

The possibility remains that the CaSR signals in a PLC-independent manner in type I taste cells. Type I taste cells express the renal outer medullary \(K^+\) channel on their apical membrane, where this channel might play a role in the recycling of the \(K^+\) that accumulates in the restricted spaces between type II and type III cells\(^{(27)}\). This scenario would be reminiscent of the thick ascending limb of the kidney, where the activation of the basolateral CaSR has been shown to inhibit apical renal outer medullary \(K^+\) through signalling pathways involving arachidonic acid and its metabolites\(^{(26)}\), and the type I taste cell CaSR may signal in a similar manner (Fig. 2).

Conversely, San Gabriel et al.\(^{(22)}\) and Maruyama et al.\(^{(29)}\) have demonstrated expression of the CaSR in a subset of taste cells that express either neural cell adhesion molecule (NCAM) (a marker of type III cells) or PLC\(\beta\)2 (a marker of type II cells) using immunofluorescence. CaSR-positive, PLC\(\beta\)2-expressing type II cells did not express one of the subunits required for the sweet/umami taste receptors, T1R3\(^{(29)}\); however, whether other receptors, such as the bitter T2R receptor, are co-expressed in CaSR-positive type II taste cells is currently unknown.

Interestingly, recent work\(^{(30)}\) has demonstrated that in CaSR-expressing HEK-293 cells this receptor may be stimulated by the bitter compound denatonium in the millimolar range. Similar to other small peptides, such as glutathione and \(\gamma\)-glutamyl peptides\(^{(15,16)}\), it seems to have a positive allosteric effect on \(\text{Ca}^{2+}\) concentration–response curves, although whether denatonium stimulates the CaSR in taste cells is unknown\(^{(30)}\).

The exposure of CaSR-expressing type III taste cells to \(\gamma\)-amino acids (\(\gamma\)-Phe and Arg), \(\gamma\)-glutamyl peptides (such as glutathione and \(\gamma\)-glutamyl-valine-glycine) and calcimetics (cinacalcet) has been shown to evoke intracellular \(\text{Ca}^{2+}(\text{Ca}^{2+})\) transients, which are ablated by the non-specific PLC inhibitor U73122\(^{(22,23)}\). High concentrations (3 \(\mu\)M) of the negative CaSR allosteric modulator, the ‘calcilytic’ NPS 2143, have also been shown to inhibit \(\gamma\)-glutamyl-valine-glycine-mediated \(\text{Ca}^{2+}\) responses, suggesting that these responses might be mediated through the activation of the CaSR (Fig. 2)\(^{(29)}\).

Although the majority of this work has been completed in rodent taste cells, there is evidence that the CaSR plays a role in human taste transduction. Human sensory analysis has demonstrated that a number of CaSR activators, including glutathione and \(\gamma\)-glutamyl-valine-glycine, act as kokumi taste substances\(^{(31)}\) enhancing sweet, salty and umami tastes without producing a taste of their own. There seems to be a positive correlation between kokumi taste intensity and CaSR agonist activity, as determined by the half maximal effective concentration (EC\(_{50}\)) values and kokumi taste intensity. A total of six \(\gamma\)-glutamyl peptides were tested for kokumi taste intensity by a panel of assessors. The intensity of kokumi taste was quantified in reference to the glutathione (GSH) concentration required to achieve an equivalent intensity of taste sensation. EC\(_{50}\) values for these substances were determined by measuring agonist-evoked increase in intracellular \(\text{Ca}^{2+}\) concentrations in HEK-293 cells transiently expressing human CaSR. Substances with stronger kokumi taste intensity exhibited a higher potency for CaSR activation than substances with lower kokumi taste intensity. Data were obtained from Ohsu et al.\(^{(32)}\) and redrawn. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)

![Fig. 2. Relationship between calcium-sensing receptor (CaSR) half maximal effective concentration (EC\(_{50}\)) values and kokumi taste intensity. A total of six \(\gamma\)-glutamyl peptides were tested for kokumi taste intensity by a panel of assessors. The intensity of kokumi taste was quantified in reference to the glutathione (GSH) concentration required to achieve an equivalent intensity of taste sensation. EC\(_{50}\) values for these substances were determined by measuring agonist-evoked increase in intracellular \(\text{Ca}^{2+}\) concentrations in HEK-293 cells transiently expressing human CaSR. Substances with stronger kokumi taste intensity exhibited a higher potency for CaSR activation than substances with lower kokumi taste intensity. Data were obtained from Ohsu et al.\(^{(32)}\) and redrawn. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)](image-url)
Calcium-sensing receptor as a nutrient sensor

Fig. 3. Proposed roles of the calcium-sensing receptor (CaSR) within taste cells. This diagram depicts the proposed roles and signalling pathways for the CaSR in type I, II and III taste cells. In this figure, the CaSR is positioned on the membrane that is most appropriate for its postulated role. (1) In type I (glial-like) cells, activation of the basolateral CaSR may be linked to the regulation of potassium recycling by the apical renal outer medullary potassium (ROMK) channel, similar to its role in the kidney. (2) The CaSR is most probably co-expressed in type II (receptor) cells with T2R receptors on the luminal membrane, where it may play a role in the transduction of both bitter taste (oral Ca\(^{2+}\)/denatonium) and kokumi taste (L-amino acids (L-AA)/\(\gamma\)-glutamyl). Activation of CaSR homodimers, or possible CaSR/T2R heterodimers, leads to activation of the G-protein gustducin (\(\alpha\)gust), phospholipase C \(\beta\) (PLC\(\beta\)) and ATP release through the functions of the Na\(^{+}\)/K\(^{+}\)-ATPase (ATPase). Increased intracellular Ca\(^{2+}\) concentrations lead to the depolarisation of the cell through the actions of the Na\(^{+}\)/K\(^{+}\) channel transient receptor potential cation channel, subfamily M, member 5 (Trpm5), delayed rectifying potassium channels (K\(\text{DR}\) channels) and voltage-gated calcium channels (VGCC). Furthermore, the cells release ATP through pannexin 1 (Panx1), exciting the ATP receptors P2Y and P2X on sensory afferent fibres (25).

(3) In type III presynaptic cells, activation of the apical CaSR by \(\gamma\)-glutamyl peptides leads to an increase in intracellular Ca\(^{2+}\) concentrations by a PLC-dependent pathway. An increase in intracellular Ca\(^{2+}\) concentrations in type III cells is linked to the release of the serotonin 5-hydroxytryptamine (5-HT), which can inhibit type II receptor cells; however, whether this occurs in a CaSR-dependent manner is currently unknown. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)

with aqueous Ca-containing solutions tasting quite bitter to humans (34). Interestingly, Ca deprivation has been shown to increase the palatability of Ca in rodents (35). The exact mechanism by which animals detect ‘taste’ Ca is still yet to be fully elucidated; however, previous work (33) has implicated the involvement of the T1R3 receptor. It has been suggested that the T1R3 receptor may heterodimerise with the CaSR to form a functional Ca\(^{2+}\) sensor in type II taste cells (33); however, there is no evidence to date that the expression of the CaSR might be a drug target for the treatment of colon cancer.

Recent studies carried out by Geibel & Hebert (35) have demonstrated that the CaSR, expressed on both the apical and basolateral membranes of colonic crypts, plays a fundamental role in the colon in NaCl and water transport and raises the possibility of using CaSR-based therapeutics to prevent toxin-induced secretory diarrhoea, one of the most debilitating conditions in underdeveloped countries. Luminal Ca\(^{2+}\) also promotes gut epithelial differentiation, while CaSR-mediated signalling suppresses gut cell proliferation while preserving epithelial integrity. Dietary Ca\(^{2+}\) intake is associated with a reduced risk of colon cancer and CaSR expression is absent in colon cancer specimens while being highly abundant in normal tissue from the same patients (see Rogers et al. (38) for a review). While a definitive and direct link between loss of CaSR expression and malignant transformation in the gut remains to be elucidated, it has been hypothesised that the CaSR might be a drug target for the treatment of colon cancer.

The CaSR is present in the stomach, where its activation stimulates the secretion of gastrin (by G cells) and of H\(^{+}\) (by antral cells) (reviewed by Geibel & Hebert (35)). In gastrin-secreting G cells, the CaSR is expressed on both the apical and basolateral membranes (36), suggesting that they have the ability to respond to changes in both the luminal contents and blood (19), whereas in parietal cells, the CaSR is expressed only on the basolateral membrane (18), which could allow the stimulation of gastric acid secretion by intestinal absorbed L-amino acids (39).}

S19
small intestine is a major regulator for the release of bile by the gall bladder, as well as the secretion of digestive enzymes from the pancreas\(^5\). CCK also acts as a satiety hormone, reducing food intake in various species, including humans\(^4\).

Due to the difficulties in obtaining sufficient amounts of homogeneous I cells from intestinal tissue, initial experiments examining the cellular mechanism by which aromatic amino acids mediate CCK secretion had focused on the murine enteroendocrine cell line STC-1. Here, L-Phe was shown to stimulate CCK secretion in a Ca\(^{2+}\)-dependent manner (Fig. 4(a) and (b))\(^{45}\). L-Phe also increased Ca\(^{2+}\) concentrations and Ca\(^{2+}\) channel activity, while the Ca\(^{2+}\) channel blocker diltiazem inhibited CCK secretion\(^{45}\). Phe-mediated secretion is also stereoselective for the natural l-isomer (Fig. 4(a)). High concentrations of the calcylctic NPS 2143 abolished l-Phe-stimulated CCK secretion, suggesting that the CaSR may play a role in l-Phe mediated CCK secretion in STC-1 cells. Consistent with this hypothesis, CaSR mRNA expression was detected in STC-1 cells using RT-PCR\(^{46}\). Recent work\(^{47}\) has also demonstrated that the STC-1 cells respond to protein hydrolysates (such as egg albumin, meat, potato, casein and soyabean) with an increase in CCK secretion, which is suppressed in the presence of NPS 2143, except for meat hydrolysate-induced CCK secretion. Together, these studies strongly support a role for the CaSR as an amino acid sensor in these cells.

The involvement of the CaSR in the mediation of CCK secretion has been elucidated by two groups using bacterial artificial chromosome transgenic mice, which permitted the identification of specific cell types using enhanced green fluorescent protein (eGFP). This elegant approach has permitted the isolation of CCK-secreting cells from CCK–eGFP bacterial artificial chromosome transgenic mice by fluorescence-activated cell sorting\(^{48,49}\).

The first such study, carried out by Liou et al.\(^{48}\), used fluorescence-activated cell sorting to isolate native CCK-secreting duodenal I cells from CCK–eGFP bacterial artificial chromosome transgenic mice. Using quantitative RT-PCR, these isolated CCK–eGFP cells were shown to express CaSR mRNA transcripts at a level approximately 900-fold higher than that in non-eGFP-expressing cells, and the presence of CaSR protein was confirmed with immunofluorescence. The exposure of isolated I cells to phenylalanine induced intracellular Ca\(^{2+}\) influx, which was Ca\(^{2+}\)-dependent and stereoselective for l-Phe. L-Phe-dependent CCK secretion in native I cells was enhanced in the presence of supraphysiological Ca\(^{2+}\) concentrations, indicating a synergistic effect of Ca\(^{2+}\) and this amino acid. Interestingly, supraphysiological Ca\(^{2+}\) concentrations alone were unable to evoke an increase in CCK secretion. Based on these results, the authors concluded that the CaSR acts as an amino acid sensor in this physiological setting\(^{48}\).

Deletion of the CaSR from CCK–eGFP I cells did not affect basal CCK secretion; however, l-Phe-mediated Ca\(^{2+}\) influx was lost. Furthermore, L-Phe and supraphysiological Ca\(^{2+}\) concentrations surprisingly suppressed CCK secretion by approximately 20–30% in these cells, compared with basal levels, suggesting that not only is the CaSR required for L-Phe-mediated CCK secretion, but also the absence of a fully functional receptor may inhibit l-amino acid-induced CCK secretion\(^{48}\).

The second study, carried out by Wang and colleagues, examined CCK-secreting intestinal mucosal cells in CCK–eGFP bacterial artificial chromosome transgenic mice. Expression of the CaSR was confirmed with quantitative RT-PCR and immunofluorescence and was found to be localised in both the apical and basolateral regions of CCK–eGFP cells, similar to that shown in the study carried out by Liou et al.\(^{48}\). Aromatic amino acids L-Phe and L-Trp, but not the non-aromatic amino acid L-Ala, caused transient increases in Ca\(^{2+}\) concentrations and stimulated CCK secretion. Antagonisation of the CaSR with the calcylctic Calhex 231 blocked aromatic amino acid-mediated CCK secretion, without affecting the effect of hyperpolarising concentrations of KCl, again pointing to a role for the CaSR in the modulation of the effects of certain amino acids on CCK secretion\(^{49}\).

Recently, the CaSR has also been implicated in the regulation of K- and L-cell activity in response to l-amino acids\(^{50}\). Isolated loops of the rat small intestine were used to quantify the
secretion of three anti-diabetic gut peptides (gluco-indulinitropeptide, glucagon-like peptide 1 and peptide tyrosine tyrosine) in response to a number of L-amino acids. L-Phe, L-Trp, L-Arg, L-Asn and L-Gln induced the secretion of gluco-indulinitropic peptide, glucagon-like peptide 1 and peptide tyrosine tyrosine in the presence of physiological Ca$^{2+}$ concentrations (i.e. 1-2.5mM). Characteristic of a CaSR-mediated response, l- amino acid-induced secretion responses were abolished in the absence of Ca$^{2+}$ for all the three peptides. High concentrations of the CaSR antagonist Calhex 231 suppressed l-amino acid acid secretion responses to various degrees, with the exception of l-Gln-stimulated glucagon-like peptide 1 secretion. Inhibition of the CaSR by Calhex 231 was most efficient at suppressing aromatic amino acid responses, perhaps unsurprisingly as it is the most potent CaSR ligand. Furthermore, the addition of a CaSR allosteric tyrosine secretion by L-amino acids further enhanced secretion to a maximal level, while an increase in Ca$^{2+}$ concentrations increased the potency of L-Phe-induced L/K-cell response.

Summary and conclusion

The role of the CaSR in nutrient sensing within the GI system continues to evolve with time. Previous studies have demonstrated that a protein-rich diet improves bone health and is associated with a reduced risk of fracture and an improved post-fracture recovery, underlying a link between dietary protein intake and Ca metabolism. New developments, presented in this review article, implicate the involvement of the CaSR in the modulation of appetite and control of satiety and anti-diabetic hormone secretion in response to amino acids/dietary Ca. Overall, these findings present the CaSR as a possible new therapeutic target in the ongoing fight against obesity and osteoporosis and their related disorders.

Acknowledgements

The authors are grateful to Professor Arthur Conigrave and Professor Steve Simpson from the University of Sydney for allowing the inclusion of previously unpublished CCK secretion data obtained by S. C. B. in their laboratory. They acknowledge the Marie Curie ITN ‘Multifaceted CaSR’ for providing financial support (grant 264663) to D. R.). T. S. D. is a recipient of a BBSRC-CASE studentship. The authors’ contributions are as follows: S. C. B. prepared the manuscript; T. S. D. and M. S. assisted in revising the manuscript and preparing the figures; D. R. was involved in the preparation and editing of the manuscript. All the authors read and approved the final manuscript.

The authors have no conflicts of interest to declare.

References
